{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:45:40Z","timestamp":1789422340399,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2018,12,18]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background and aims<\/jats:title>\n                  <jats:p>This article provides expert guidance on the management of pruritus symptoms in patients receiving obeticholic acid (OCA) as treatment for primary biliary cholangitis (PBC). PBC is a chronic, autoimmune cholestatic liver disease that affects intrahepatic bile ducts. If not adequately treated, PBC can lead to cholestasis and end-stage liver disease, which may require transplant. Timely treatment is therefore vital to patient health. Pruritus is a common symptom in patients with PBC. Additionally, the use of OCA to treat PBC can contribute to increased pruritus severity in some patients, adding to patient discomfort, decreasing patient quality of life (QoL), and potentially affecting patient adherence to OCA treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In May 2018, a group of physician experts from the fields of gastroenterology, hepatology, and psychiatry met to discuss the management of pruritus in OCA-treated patients with PBC. Recognizing the importance of optimizing treatment for PBC, these experts developed recommendations for managing pruritus symptoms in the OCA-treated PBC patient based on their experience in clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>These recommendations include a comprehensive list of management strategies (including over-the-counter, prescription, and alternative therapies), guidance on titration of OCA to minimize pruritus severity, and an algorithm that outlines a practical approach to follow up with patients receiving OCA, to better assess and manage pruritus symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pruritus associated with OCA therapy is dose dependent and often manageable, and with the proper education and tools, most pruritus cases can be effectively managed to minimize treatment discontinuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2018-000256","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T03:35:14Z","timestamp":1549078514000},"page":"e000256","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel"],"prefix":"10.1136","volume":"6","author":[{"given":"Jennifer","family":"Pate","sequence":"first","affiliation":[{"name":"Baylor St Luke\u2019s Medical Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juilo A","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Transplant and Hepatopancreatobiliary Institute, Verity Medical Foundation, San Jose, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine T","family":"Frenette","sequence":"additional","affiliation":[{"name":"Division of Organ Transplantation, Scripps Clinic\/Scripps Green Hospital, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Goel","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Manch","sequence":"additional","affiliation":[{"name":"Institute for Liver Health, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A","family":"Mena","sequence":"additional","affiliation":[{"name":"Pasadena Liver Center, Pasadena, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Pockros","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Scripps Clinic\/Scripps Translational Science Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjaya K","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Division of Transplant Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kidist K","family":"Yimam","sequence":"additional","affiliation":[{"name":"Autoimmune Liver Disease Program, California Pacific Medical Center, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G","family":"Gish","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"2025073013185018000_6.1.e000256.1","unstructured":"Pandit S , Samant H . Primary biliary cholangitis (primary biliary cirrhosis). In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC, 2018."},{"key":"2025073013185018000_6.1.e000256.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOG.0000000000000254","article-title":"Management of symptom complexes in primary biliary cholangitis","volume":"32","author":"Kuo","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"2025073013185018000_6.1.e000256.3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"The Lancet"},{"key":"2025073013185018000_6.1.e000256.4","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"The Lancet"},{"key":"2025073013185018000_6.1.e000256.5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-009-0164-5","article-title":"Primary biliary cirrhosis","volume":"31","author":"Hohenester","year":"2009","journal-title":"Semin Immunopathol"},{"key":"2025073013185018000_6.1.e000256.6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"138","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"2025073013185018000_6.1.e000256.7","unstructured":"Urso . prescribing information. Bridgewater NJ: Aptalis Pharma US, 2013."},{"key":"2025073013185018000_6.1.e000256.8","unstructured":"Ocaliva . prescribing information. New York NY: Intercept Pharmaceuticals, 2016."},{"key":"2025073013185018000_6.1.e000256.9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clinre.2016.09.006","article-title":"Obeticholic acid in primary biliary cholangitis","volume":"41","author":"Erlinger","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025073013185018000_6.1.e000256.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"2025073013185018000_6.1.e000256.11","unstructured":"Intercept Pharmaceuticals Inc , 2018. Phase 4 study of obeticholic acid evaluating clinical outcomes in patients with primary biliary cholangitis (COBALT). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02308111 [Accessed 27 Jul 2018]."},{"key":"2025073013185018000_6.1.e000256.12","first-page":"154","article-title":"Update on new drugs and those in development for the treatment of primary biliary cholangitis","volume":"14","author":"Bahar","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"2025073013185018000_6.1.e000256.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2025073013185018000_6.1.e000256.14","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"2025073013185018000_6.1.e000256.15","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1056\/NEJMe1804945","article-title":"Progress in primary biliary cholangitis","volume":"378","author":"Carey","year":"2018","journal-title":"N Engl J Med"},{"key":"2025073013185018000_6.1.e000256.16","unstructured":"Fenofibrate Tablets [prescribing information] , 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204475Orig1s000lbl.pdf [Accessed 9 Oct 2018]."},{"key":"2025073013185018000_6.1.e000256.17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mcna.2013.09.002","article-title":"Cholestatic liver disease","volume":"98","author":"Gossard","year":"2014","journal-title":"Med Clin North Am"},{"key":"2025073013185018000_6.1.e000256.18","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp15X685477"},{"key":"2025073013185018000_6.1.e000256.19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i19.3418"},{"key":"2025073013185018000_6.1.e000256.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/295891","article-title":"Management of pruritus in chronic liver disease","volume":"2015","author":"Bhalerao","year":"2015","journal-title":"Dermatol Res Pract"},{"key":"2025073013185018000_6.1.e000256.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjmed.2017.01.037","article-title":"Management of pruritus in primary biliary cholangitis: a narrative review","volume":"130","author":"Trivedi","year":"2017","journal-title":"Am J Med"},{"key":"2025073013185018000_6.1.e000256.22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025073013185018000_6.1.e000256.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2010.10.007"},{"key":"2025073013185018000_6.1.e000256.24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.25847","article-title":"Pathogenesis of cholestatic itch: old questions, new answers, and future opportunities","volume":"56","author":"Jones","year":"2012","journal-title":"Hepatology"},{"key":"2025073013185018000_6.1.e000256.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64551"},{"key":"2025073013185018000_6.1.e000256.26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.mehy.2017.11.002","article-title":"The pruritus of cholestasis: From bile acids to opiate agonists: relevant after all these years","volume":"110","author":"Bergasa","year":"2018","journal-title":"Med Hypotheses"},{"key":"2025073013185018000_6.1.e000256.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29569"},{"key":"2025073013185018000_6.1.e000256.28","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1265"},{"key":"2025073013185018000_6.1.e000256.29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"2025073013185018000_6.1.e000256.30","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065862"},{"key":"2025073013185018000_6.1.e000256.31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.dld.2010.01.004","article-title":"A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis","volume":"42","author":"Montali","year":"2010","journal-title":"Dig Liver Dis"},{"key":"2025073013185018000_6.1.e000256.32","doi-asserted-by":"crossref","first-page":"19008","DOI":"10.1038\/srep19008","article-title":"Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists","volume":"6","author":"Sepe","year":"2016","journal-title":"Sci Rep"},{"key":"2025073013185018000_6.1.e000256.33","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/S0168-8278(18)30665-2","article-title":"Durable response in the markers of cholestasis through 36 months of open-label extension study of obeticholic acid in primary biliary cholangitis","volume":"68","author":"Trauner","year":"2018","journal-title":"J Hepatol"},{"key":"2025073013185018000_6.1.e000256.34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clindermatol.2011.11.004","article-title":"Psychosomatic factors in pruritus","volume":"31","author":"Tey","year":"2013","journal-title":"Clin Dermatol"},{"key":"2025073013185018000_6.1.e000256.35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"2025073013185018000_6.1.e000256.36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/1756283X17728669","article-title":"Novel strategies and therapeutic options for the management of primary biliary cholangitis","volume":"10","author":"Khanna","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"2025073013185018000_6.1.e000256.37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21370"},{"key":"2025073013185018000_6.1.e000256.38","doi-asserted-by":"crossref","first-page":"e00309","DOI":"10.1002\/prp2.309","article-title":"Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug","volume":"5","author":"Schlit","year":"2017","journal-title":"Pharmacol Res Perspect"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2018-000256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:19:03Z","timestamp":1753906743000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2018-000256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,1]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/bmjgast-2018-000256"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2018-000256","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}